Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A11QVV0
Mon, 04.03.2024       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million HealthCare Royalty to purchase royalties from worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent ZircaixTM (TLX250-CDx) H [ … ]
Technical analysis
To the publication
Wed, 29.11.2023       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Announces Changes to the Executive Management Board Ladenburg, Germany, 29 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Dr. Jan Schmidt-Brand, Chief Executive Officer (CEO) of Heidelberg Pharma AG and Ma [ … ]
Technical analysis
To the publication
Thu, 29.06.2023       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics US pharma company Eli Lilly and Company acquires all shares of ADC developer Emergence Therapeutics Heidelberg Pharma is one of the founding investors and will receive about [ … ]
Technical analysis
To the publication
Thu, 29.06.2023       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014 Heidelberg Pharma Sells Minority Shareholding in Emergence Therapeutics US pharma company Eli Lilly and Company acquires all shares of ADC developer Emergence Therapeutics Heidelberg Pharma is one of the founding investors and will receive about [ … ]
Technical analysis
To the publication
Tue, 04.10.2022       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement - Inside information pursuant to Article 17 MAR Heidelberg Pharma AG Announces Adjustment of Guidance Ladenburg, Germany, 4 October 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has adjusted its guidance for the current fiscal year published on 24 March 2022. The license agreement with the strategic partner H [ … ]
Technical analysis
To the publication
Tue, 04.10.2022       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement - Inside information pursuant to Article 17 MAR Heidelberg Pharma AG Announces Adjustment of Guidance Ladenburg, Germany, 4 October 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has adjusted its guidance for the current fiscal year published on 24 March 2022. The license agreement with the strategic partner H [ … ]
Technical analysis
To the publication
Fri, 09.09.2022       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement - Insider information pursuant to Article 17 MAR Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate Ladenburg, Germany, 9 September 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH and Take [ … ]
Technical analysis
To the publication
Fri, 09.09.2022       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement - Insider information pursuant to Article 17 MAR Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate Ladenburg, Germany, 9 September 2022 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH and Take [ … ]
Technical analysis
To the publication
Wed, 13.07.2022       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement - Inside information pursuant to Article 17 MAR Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate Ladenburg, Germany, 13 July 2022 – Heidelberg Pharma AG (FSE: HPHA) and Chiome Bioscience Inc., Tokyo, Japan, (Tokyo: 4583) toda [ … ]
Technical analysis
To the publication
Wed, 13.07.2022       Heidelberg Pharma AG
DE000A11QVV0

Ad hoc announcement - Inside information pursuant to Article 17 MAR Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate Ladenburg, Germany, 13 July 2022 – Heidelberg Pharma AG (FSE: HPHA) and Chiome Bioscience Inc., Tokyo, Japan, (Tokyo: 4583) toda [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 07.07.2024, Calendar Week 27, 189th day of the year, 177 days remaining until EoY.